Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, recently sponsored the 9 th Symposium on Targeted Alpha Therapy, held in Warsaw, Poland on May 19-21. Symposium organizers included the Institute for Transuranium Elements of the European Commission and other sponsors include the U.S. Department of Energy. The latest developments in alpha emitter therapy were discussed, such as clinical experiences with alpha emitters including actinium.

Dr. Joseph G. Jurcic, Professor of Medicine at Columbia University Medical Center and Chairman of Actinium’s Clinical Advisory Board, presented “Targeted Alpha-Particle Therapy with Actinium- 225 (225Ac)-Lintuzumab for Acute Myeloid Leukemia (AML) Alone and in Combination with LowDose Cytarabine (LDAC)”. A review of the target (CD33), the antibody (Lintuzumab, also called HuM195) and the payload (actinium-225, a potent alpha-emitter) was given. He also provided a clinical update on the ongoing Phase I/II study of Actimab-A, the Company’s alpha-emitting radiolabeled antibody, being developed for older patients with newly diagnosed acute myeloid leukemia (AML).

The Company recently announced that it began the fourth and last cohort (2.0 μCi/kg per dose) in this trial. It is expected that the MTD will be reached at this level, and thereafter the Company will move to the Phase 2 portion of the trial. Thus far, Actinium has consistently observed anti-leukemic activity across four clinical trials of its HuM195-actinium-225 construct, including two trials of its first generation compound, Bismab-A. The safety profile also appears to be acceptable, with moderate toxicities commonly seen with even mildest treatments in these extremely sick patients who presently has few effective therapeutic options.

Dr. Jurcic is Director of the Hematologic Malignancies Section of the Hematology/Oncology Division and Professor of Clinical Medicine at Columbia University Medical Center. He is a hematologist/oncologist focusing on the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome. His research interests include acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy for leukemia, development of novel small molecule inhibitors for leukemia and molecular monitoring of minimal residual disease. He is the primary investigator for the current Actimab-A clinical trial and Clinical Advisory Board Chairman. He received his medical degree from the University of Pennsylvania and completed his fellowship in Hematology-Oncology at Memorial Sloan-Kettering Cancer Center.(Original Source)

Shares of Actinium Pharmaceuticals opened today at $3.55 and are currently trading up %11.33 at $3.90. ATNM has a 1-year high of $13.70 and a 1-year low of $2.31. The stock’s 50-day moving average is $2.86 and its 200-day moving average is $4.16.

On the ratings front, MLV & Co. analyst Arlinda Lee reiterated a Buy rating on ATNM, with a price target of $15, in a report issued on March 17. The current price target implies an upside of 271% from current levels. According to, Lee has a total average return of 2.6%, a 53.8% success rate, and is ranked #1652 out of 3610 analysts.

Actinium Pharmaceuticals Inc is a biopharmaceutical company which develops drugs for treatment of cancer. It is a development stage company.